Literature DB >> 2849489

Serum concentration of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women.

L Tjellesen1, L Hummer, C Christiansen, P Rødbro.   

Abstract

Serum concentrations of vitamin D metabolites were measured in 19 healthy premenopausal women before and during treatment with 4000 IU per day of either vitamin D2 or vitamin D3 for 8 weeks. Vitamin D2 treatment increased the serum concentration of 25(OH)D2, but a corresponding decrease in 25(OH)D3 resulted in an unchanged value for total 25(OH)D. The serum concentration of the D3 dihydroxy metabolites was also significantly decreased. Vitamin D3 treatment increased the serum concentrations of 25(OH)D3 and D3 dihydroxy metabolites. The serum concentration of 1,25(OH)2D did not change in either of the treatment groups. We conclude that vitamin D2 and vitamin D3 given in the same doses in international units have a different effect on the serum concentration of vitamin D metabolites and biochemical indices of calcium metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2849489

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  19 in total

1.  Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake.

Authors:  Pierre J Meunier; Cecile Jenvrin; Françoise Munoz; Viviane de la Gueronnière; Patrick Garnero; Michèle Menz
Journal:  Osteoporos Int       Date:  2005-03-03       Impact factor: 4.507

2.  Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults.

Authors:  N Binkley; D Gemar; J Engelke; R Gangnon; R Ramamurthy; D Krueger; M K Drezner
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

3.  Comparative efficacy and safety of different doses of ergocalciferol supplementation in patients with metabolic syndrome.

Authors:  Nakarin Sansanayudh; Supakit Wongwiwatthananukit; Nongluk Phetkrajaysang; Sarinee Krittiyanunt
Journal:  Int J Clin Pharm       Date:  2014-05-23

4.  Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.

Authors:  James B Wetmore; Cassandra Kimber; Jonathan D Mahnken; Jason R Stubbs
Journal:  Br J Nutr       Date:  2017-01-09       Impact factor: 3.718

5.  Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach.

Authors:  B Oliveri; S R Mastaglia; G M Brito; M Seijo; G A Keller; J Somoza; R A Diez; G Di Girolamo
Journal:  Eur J Clin Nutr       Date:  2015-03-18       Impact factor: 4.016

6.  Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.

Authors:  Eric N Taylor; Andrew N Hoofnagle; Gary C Curhan
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-26       Impact factor: 8.237

Review 7.  Benefit-risk assessment of vitamin D supplementation.

Authors:  H A Bischoff-Ferrari; A Shao; B Dawson-Hughes; J Hathcock; E Giovannucci; W C Willett
Journal:  Osteoporos Int       Date:  2009-12-03       Impact factor: 4.507

8.  Vitamin d deficiency in cystic fibrosis.

Authors:  William B Hall; Amy A Sparks; Robert M Aris
Journal:  Int J Endocrinol       Date:  2010-01-28       Impact factor: 3.257

Review 9.  Vitamin D during pregnancy: why observational studies suggest deficiency and interventional studies show no improvement in clinical outcomes? A narrative review.

Authors:  S N Karras; P Anagnostis; D Naughton; C Annweiler; A Petroczi; D G Goulis
Journal:  J Endocrinol Invest       Date:  2015-07-29       Impact factor: 4.256

10.  Comparison of vitamin D metabolism in early healthy and late osteoporotic postmenopausal women.

Authors:  D Hartwell; B J Riis; C Christiansen
Journal:  Calcif Tissue Int       Date:  1990-12       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.